Table 4. Participation, banking rates, and baseline characteristics of surgical sub-cohorts in SUPER-GUC.
| Characteristic | SUPER-PC-RP | SUPER-RCC-Nx | SUPER-UC-TURB | SUPER-UC-Cx | SUPER-UC-UTUC |
|---|---|---|---|---|---|
| No. of patients enrolled | 765 | 762 | 859 | 170 | 163 |
| Participation ratea | 765/836 (91.5) | 762/853 (89.3) | 859/964 (89.1) | 170/191 (89.0) | 163/175 (93.1) |
| Bio-specimen sampling rate | 758/765 (99.1) | 733/762 (96.2) | 829/859 (96.5) | 155/170 (91.2) | 155/163 (95.1) |
| Tumor banking | 463/765 (60.5) | 565/762 (74.1) | 489/859 (56.9) | 117/170 (68.8) | 129/163 (79.1) |
| Baseline characteristics | |||||
| Age (y) | 68.7±6.6 | 59.4±12.4 | 68.9±11.9 | 67.0±10.9 | 68.5±9.9 |
| Sex | |||||
| Male | 765 (100.0) | 521 (68.4) | 687 (80.0) | 128 (75.3) | 113 (69.3) |
| Female | 0 (0.0) | 241(31.6) | 172 (20.0)b | 42 (24.7) | 50 (30.7) |
| Clinical T stage | |||||
| ≤T1 | 674 (88.1) | 658 (86.4) | 568 (66.1) | 59 (34.7) | 123 (75.5) |
| T2 | 79 (10.3) | 63 (8.3) | 86 (10.0)c | 88 (51.8) | 17 (10.4) |
| T3 | 12 (1.6) | 38 (5.0) | - | 15 (8.8) | 22 (13.5) |
| T4 | 0 (0.0) | 3 (0.4) | - | 8 (4.7) | 1 (0.6) |
| Tx | 0 (0.0) | 0 (0.0) | 205 (23.9)d | 0 (0.0) | 0 (0.0) |
| Clinical N stage | |||||
| N0 | 672 (87.8) | 738 (96.9) | - | 145 (85.3) | 145 (89.0) |
| N+ | 86 (11.2) | 24 (3.1) | - | 25 (14.7) | 18 (11.0) |
| Nx | 7 (0.9) | 0 (0.0) | - | 0 (0.0) | 0 (0.0) |
| Clinical M stage | |||||
| M0 | 738 (96.5) | 738 (96.9) | - | 169 (99.4) | 162 (99.4) |
| M+ | 0 (0.0) | 24 (3.1) | - | 1 (0.6) | 1 (0.6) |
| Mx | 27 (3.5) | 0 (0.0) | - | 0 (0.0) | 0 (0.0) |
Values are presented as number only, number/total number (%), mean±standard deviation, or number (%).
SUPER, Seoul National University Prospectively Enrolled Registry; GUC, Genitourinary Cancer; PC, prostate cancer; RP, radical prostatectomy; RCC, renal cell carcinoma; Nx, nephrectomy; UC, urothelial cancer; TURB, transurethral resection of bladder tumor; Cx, cystectomy; UTUC, upper urinary tract urothelial cancer.
a:Percentage of patients enrolled among all eligible patients, b:pathologic stage of first TURB after enrolled, c:pathologic stage ≥T2, d:pathologic T0 or benign.